Mangalam Drugs and Organics standalone net profit declines 32.13 percent in the June 2022 quarter - Indiainfoline
| MANGALAM | 102.39 3.38 3.20% |
About 62% of Mangalam Drugs' investor base is looking to short. The analysis of overall sentiment of trading Mangalam Drugs And stock suggests that many investors are alarmed at this time. The current market sentiment, together with Mangalam Drugs' historical and current headlines, can help investors time the market. In addition, many technical investors use Mangalam Drugs And stock news signals to limit their universe of possible portfolio assets.
Mangalam |
Mangalam Drugs and Organics standalone net profit declines 32.13 percent in the June 2022 quarter Indiainfoline
Read at news.google.com
 |
Mangalam Drugs Fundamental Analysis
We analyze Mangalam Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mangalam Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mangalam Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Mangalam Drugs is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Mangalam Drugs And Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mangalam Drugs stock to make a market-neutral strategy. Peer analysis of Mangalam Drugs could also be used in its relative valuation, which is a method of valuing Mangalam Drugs by comparing valuation metrics with similar companies.
Peers
Mangalam Drugs Related Equities
Complementary Tools for Mangalam Stock analysis
When running Mangalam Drugs' price analysis, check to measure Mangalam Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangalam Drugs is operating at the current time. Most of Mangalam Drugs' value examination focuses on studying past and present price action to predict the probability of Mangalam Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangalam Drugs' price. Additionally, you may evaluate how the addition of Mangalam Drugs to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |